In prostate cancer, the focus is on PIP5K1α inhibitors and GPRC5A, in breast cancer, on TGFβ and BMP signaling pathways, and in lung cancer, on the role of LIGHT in osteolytic destruction [67]. This evidence concerns the gene TGFB1 and prostate carcinoma.